Partner with BioCopy to Unlock Intracellular Cancer Targets
The Next Frontier in Differentiated Cancer Drug Discovery.
Where do you want to start?
Why BioCopy
One AI-driven platform. De-risked TCRm antibodies. Multiple paths to partnership.
BioCopy’s proprietary ValidaTe® platform integrates AI-driven screening and prediction to discover TCRm antibodies against intracellular cancer targets with a differentiated safety profile. Our lead program, MAGE-A4, is the most advanced asset available for partnering, backed by a broader pipeline with strong commercial potential across multiple cancer indications of high unmet medical need.
Partner with us to access a validated, integrated discovery engine — from target credentialing through IND-enabling development.
Partnering Model
Flexible collaboration, tailored to where you want to start.
We offer three flexible engagement models designed to meet partners at different stages of their development journey:
Model 1 — Portfolio Program Participation:
Joint advancement of BioCopy’s existing programs through licensing, option-to-license, or co-development structures, enabling partners to enter at a later stage with selected assets.
Model 2 — Discovery & Preclinical Partnership:
End-to-end collaboration from target identification through IND-enabling development, leveraging BioCopy’s integrated ValidaTe® platform and pHLA expertise.
Model 3 — Early-Stage Catalyst:
Partner-led discovery supported by BioCopy’s proprietary platforms, data, and pHLA/TCRm expertise, accelerating programs from target concept to validated candidates.
Each model can be tailored or combined to match a partner’s strategic priorities, internal capabilities, and desired point of entry.
Partnership Inquiries
Let’s discuss how BioCopy can support your pipeline
We welcome inquiries from pharmaceutical and biotechnology companies interested in co-developing differentiated TCRm-based therapies, accessing the ValidaTe® platform, licensing BioCopy programs, or exploring tailored discovery collaborations.
For partnering opportunities, please contact:
Susanne Ziemons, Senior BD Executive, at susanne.ziemons@biocopy.com or +49 174 9050 733.
Get in touch
Let’s redefine drug discovery —
together.
Whether you want to partner, invest, join, or simply learn more — tell us what you’re working on. We’ll route you to the right person.
- Validated anti-pHLA therapeutics — not just predictions
- Confidential by default · NDA on request
- No sales calls — only direct conversations with our team
Send us a message
By submitting, you agree to our privacy policy. We'll never share your data.